NCT06650761View on ClinicalTrials.gov

A Phase I Study of CDX-622

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Healthy Participants
Interventions
DRUG

CDX-622

Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622

DRUG

Normal Saline

Up to 4 infusions or 6 SC injections of normal saline

Trial Locations (1)

85283

RECRUITING

Celerion, Inc., Tempe

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT06650761 - A Phase I Study of CDX-622 | Biotech Hunter | Biotech Hunter